Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. NOW
3. USO
4. NVDA
5. SPY
6. AMD
7. DHR
8. TSLA
9. GM
10. SMCI

Go back to Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting
(NASDAQ: TRIL) Delayed: 19.86 --0 (-0%)
Previous Close $19.86    52 Week High $17.70 
Open $19.86    52 Week Low $6.62 
Day High $19.86    P/E N/A 
Day Low $19.86    EPS $0.00 
Volume 7       

(NASDAQ: TRIL) Delayed: 19.86 --0 (-0%)
Previous Close $19.86    52 Week High $17.70 
Open $19.86    52 Week Low $6.62 
Day High $19.86    P/E N/A 
Day Low $19.86    EPS $0.00 
Volume 7